Protein / target
Fatty-acid amide hydrolase 1
Protein at a glance
Biological role
Fatty acid amide hydrolase
Strongest disease association
Migraine Disorders
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Catalyzes the hydrolysis of endogenous amidated lipids like the sleep-inducing lipid oleamide ((9Z)-octadecenamide), the endocannabinoid anandamide (N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine), as well as other fatty amides, to their corresponding fatty acids, thereby regulating the signaling f…
View complete UniProt function annotationHide complete annotation
Catalyzes the hydrolysis of endogenous amidated lipids like the sleep-inducing lipid oleamide ((9Z)-octadecenamide), the endocannabinoid anandamide (N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine), as well as other fatty amides, to their corresponding fatty acids, thereby regulating the signaling functions of these molecules (PubMed:17015445, PubMed:19926788, PubMed:9122178). Hydrolyzes polyunsaturated substrate anandamide preferentially as compared to monounsaturated substrates (PubMed:17015445, PubMed:9122178). It can also catalyze the hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-glycerol) (PubMed:21049984). FAAH cooperates with PM20D1 in the hydrolysis of amino acid-conjugated fatty acids such as N-fatty acyl glycine and N-fatty acyl-L-serine, thereby acting as a physiological regulator of specific subsets of intracellular, but not of extracellular, N-fatty acyl amino acids (By similarity)
Subcellular location
Domains and Gene Ontology detail (18)Hide
Gene Ontology
- Ccytoskeleton
- Cendoplasmic reticulum membrane
- Cglutamatergic synapse
- Corganelle membrane
- Cpostsynapse
- Cpresynapse
- Famidase activity
- Ffatty acid amide hydrolase activity
- Fidentical protein binding
- Fmonoacylglycerol lipase activity
- Fphospholipid binding
- Parachidonate metabolic process
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Lipid & lipoprotein metabolism
- ·Catalyzes the hydrolysis of endogenous amidated lipids like the sleep-inducing lipid ole…
- ·fatty acid amide hydrolase activity
- ·phospholipid binding
- ·fatty acid catabolic process
Synaptic signalling
- ·glutamatergic synapse
- ·postsynapse
- ·presynapse
- ·regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmiss…
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Anandamide amidohydrolase inhibitor
Indicated for Acute Pain, Arthritis, Back Pain, Common Cold
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene FAAH
Gene-level evidence surfaced through the gene FAAH that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (1)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
3 compounds recorded · 1 approved · 2 in clinical development
View all recorded compounds (3)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Emerging
Protein degraders — Emerging
View underlying tractability evidence (7)Hide
Raw Open Targets tractability assessment buckets, by modality.
Safety-related annotations
Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Supplemental approval
Supplemental approval: ACETAMINOPHEN AND CODEINE (ANDA040779)
- Supplemental approval
Supplemental approval: ACETAMINOPHEN AND CODEINE PHOSPHATE (ANDA040419)
- Supplemental approval
Supplemental approval: ACETAMINOPHEN AND CODEINE PHOSPHATE (ANDA087508)
- Supplemental approval
Supplemental approval: ACETAMINOPHEN AND CODEINE PHOSPHATE (ANDA089805)
- Supplemental approval
Supplemental approval: ACETAMINOPHEN AND CODEINE PHOSPHATE (ANDA089828)
- Supplemental approval
Supplemental approval: ACETAMINOPHEN AND CODEINE PHOSPHATE (ANDA089990)
- Supplemental approval
Supplemental approval: ACETAMINOPHEN AND CODEINE PHOSPHATE (ANDA202800)
- Supplemental approval
Supplemental approval: ACETAMINOPHEN AND CODEINE PHOSPHATE (ANDA211610)
- New publicationComparison of clinical outcomes of acetaminophen IV vs PO in the peri-operative setting for laparoscopic inguinal hernia repair surgeries: A triple-blinded, randomized controlled trial.
- New publicationA randomized placebo-controlled trial of acetaminophen for prevention of post-vaccination fever in infants.
- New publicationA randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery.
- New publicationIntravenous acetaminophen vs oral ibuprofen in combination with morphine PCIA after Cesarean delivery.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.